Boxer Capital Management LLC Takes Position in Apogee Therapeutics, Inc. (NASDAQ:APGE)

Boxer Capital Management LLC acquired a new position in Apogee Therapeutics, Inc. (NASDAQ:APGE - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 86,000 shares of the company's stock, valued at approximately $3,896,000. Boxer Capital Management LLC owned about 0.19% of Apogee Therapeutics at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the stock. Optimize Financial Inc purchased a new stake in Apogee Therapeutics during the fourth quarter valued at about $203,000. Aigen Investment Management LP bought a new position in shares of Apogee Therapeutics during the fourth quarter valued at about $216,000. Commonwealth Equity Services LLC purchased a new position in shares of Apogee Therapeutics in the fourth quarter worth about $222,000. KLP Kapitalforvaltning AS purchased a new stake in Apogee Therapeutics during the 4th quarter valued at about $226,000. Finally, Tower Research Capital LLC TRC grew its position in Apogee Therapeutics by 356.6% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,287 shares of the company's stock worth $285,000 after acquiring an additional 4,910 shares during the last quarter. 79.04% of the stock is currently owned by institutional investors.

Insider Activity at Apogee Therapeutics

In other news, insider Carl Dambkowski sold 3,520 shares of the stock in a transaction that occurred on Wednesday, February 5th. The shares were sold at an average price of $40.69, for a total value of $143,228.80. Following the transaction, the insider now owns 252,623 shares in the company, valued at $10,279,229.87. This represents a 1.37 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Michael Thomas Henderson sold 10,000 shares of the business's stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $30.15, for a total transaction of $301,500.00. Following the sale, the chief executive officer now directly owns 1,292,987 shares of the company's stock, valued at approximately $38,983,558.05. The trade was a 0.77 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 33,970 shares of company stock valued at $1,241,701 over the last 90 days. Corporate insiders own 36.10% of the company's stock.

Apogee Therapeutics Trading Down 1.8 %

Apogee Therapeutics stock traded down $0.73 on Monday, hitting $39.39. 504,490 shares of the stock traded hands, compared to its average volume of 516,108. Apogee Therapeutics, Inc. has a 1 year low of $26.20 and a 1 year high of $63.50. The firm has a market cap of $1.77 billion, a P/E ratio of -16.28 and a beta of 1.70. The business's fifty day simple moving average is $35.65 and its 200 day simple moving average is $42.05.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last issued its quarterly earnings results on Monday, March 3rd. The company reported ($1.19) EPS for the quarter, missing analysts' consensus estimates of ($0.94) by ($0.25). As a group, analysts predict that Apogee Therapeutics, Inc. will post -3.09 earnings per share for the current year.

Analysts Set New Price Targets

APGE has been the topic of several analyst reports. Guggenheim reaffirmed a "buy" rating on shares of Apogee Therapeutics in a research note on Monday, February 10th. Wedbush reiterated an "outperform" rating and set a $90.00 target price on shares of Apogee Therapeutics in a report on Tuesday, March 11th. Finally, Citigroup assumed coverage on Apogee Therapeutics in a research report on Thursday, March 13th. They set a "buy" rating and a $95.00 price target for the company. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $92.17.

Apogee Therapeutics Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.